Loading…
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $62M | $-3M | $-11M | $-12M | -35.9% | 10.2% | -22.1% |
| 2024 | $56M | $-8M | $-15M | $-24M | -73.1% | -29.1% | 280.8% |
| 2023 | $79M | $2M | $-4M | $0M | -18.9% | 7.5% | -87.0% |
| 2022 | $74M | $-23M | $-30M | $-34M | -174.5% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 73.67 | 79.18 | 56.13 | 61.86 |
| Operating Revenue | - | 71 | 59.66 | 55.13 | 61.24 |
| Cost Of Revenue | - | 30.78 | 22.89 | 20.88 | 20.92 |
| Gross Profit | - | 42.89 | 56.29 | 35.26 | 40.93 |
| Operating Expense | - | 70.41 | 55.22 | 53.48 | 49.11 |
| Research And Development | - | 10.94 | 7.54 | 9.86 | 0.48 |
| Selling General And Administration | - | 59.47 | 43.91 | 40.20 | 44.37 |
| Total Expenses | - | 101.19 | 78.11 | 74.36 | 70.03 |
| Operating Income | - | -27.52 | 1.07 | -18.23 | -8.17 |
| Total Operating Income As Reported | - | -27.52 | -2.07 | -13.68 | -8.17 |
| EBITDA | - | -23.18 | 1.92 | -8.40 | -3.33 |
| Normalized EBITDA | - | -23.09 | 5.25 | -13.96 | -3.24 |
| EBIT | - | -27.55 | -1.93 | -11.91 | -7.67 |
| Interest Income | - | 0.06 | 0.32 | 0.76 | 0.59 |
| Interest Expense | - | 2.02 | 1.70 | 2.70 | 3.70 |
| Net Interest Income | - | -1.96 | -1.38 | -1.94 | -3.11 |
| Other Income Expense | - | -0.09 | -3.33 | 5.56 | -0.09 |
| Interest Income Non Operating | - | 0.06 | 0.32 | 0.76 | 0.59 |
| Interest Expense Non Operating | - | 2.02 | 1.70 | 2.70 | 3.70 |
| Net Non Operating Interest Income Expense | - | -1.96 | -1.38 | -1.94 | -3.11 |
| Pretax Income | - | -29.56 | -3.63 | -14.61 | -11.37 |
| Tax Provision | - | 0.06 | 0.22 | 0.06 | 0.06 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -0.70 | 1.17 | -0.02 |
| Net Income Continuous Operations | - | -29.63 | -3.85 | -14.67 | -11.43 |
| Net Income From Continuing And Discontinued Operation | - | -29.63 | -3.85 | -14.67 | -11.43 |
| Net Income From Continuing Operation Net Minority Interest | - | -29.63 | -3.85 | -14.67 | -11.43 |
| Net Income | - | -29.63 | -3.85 | -14.67 | -11.43 |
| Net Income Common Stockholders | - | -29.63 | -3.85 | -14.67 | -11.43 |
| Net Income Including Noncontrolling Interests | - | -29.63 | -3.85 | -14.67 | -11.43 |
| Normalized Income | - | -29.54 | -1.23 | -19.07 | -11.36 |
| Diluted NI Availto Com Stockholders | - | -29.63 | -3.85 | -14.67 | -11.43 |
| Basic Average Shares | 10.19 | 17.53 | 18.23 | 20.43 | - |
| Diluted Average Shares | 10.19 | 17.53 | 18.23 | 20.43 | - |
| Reconciled Depreciation | - | 4.36 | 3.86 | 3.52 | 4.35 |
| Reconciled Cost Of Revenue | - | 30.78 | 22.80 | 20.79 | 20.84 |
| Total Unusual Items | - | -0.09 | -3.33 | 5.56 | -0.09 |
| Total Unusual Items Excluding Goodwill | - | -0.09 | -3.33 | 5.56 | -0.09 |
| Special Income Charges | - | 0 | -3.14 | 5.68 | 0 |
| Other Special Charges | 9.54 | - | - | -5.68 | - |
| Impairment Of Capital Assets | - | 0 | 3.14 | 0 | - |
| Gain On Sale Of Security | - | -0.09 | -0.18 | -0.12 | -0.09 |
| Depreciation Amortization Depletion Income Statement | - | - | 3.77 | 3.42 | 4.26 |
| Depreciation And Amortization In Income Statement | - | - | 3.77 | 3.42 | 4.26 |
| Amortization | - | - | 3.77 | 3.42 | 4.26 |
| Amortization Of Intangibles Income Statement | - | - | 3.77 | 3.42 | 4.26 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Journey Medical Corporationthis co. | DERM | $171M | -14.98 | 5.38 | -35.9% | -51.87 |
| MediWound Ltd. | MDWD | $186M | -7.78 | 4.26 | -54.7% | -8.81 |
| Stereotaxis, Inc. | STXS | $184M | -8.49 | 13.63 | -160.5% | -8.55 |
| Quanterix Corporation | QTRX | $179M | -1.67 | 0.61 | -36.2% | -2.05 |
| Inogen, Inc. | INGN | $171M | -7.51 |
| - |
| - |
| - |
| - |
| - |
| - |
| 0.89 |
| -11.8% |
| -8.86 |
| ADC Therapeutics SA | ADCT | $168M | -1.18 | -0.90 | 76.7% | -0.27 |
| Protalix BioTherapeutics, Inc. | PLX | $162M | - | 3.36 | -13.7% | - |
| Korro Bio, Inc. | KRRO | $161M | -1.38 | 3.13 | -228.0% | -2.20 |
| CVRx, Inc. | CVRX | $156M | - | 3.97 | -135.6% | - |
| Peer Median | - | -4.59 | 3.25 | -45.5% | -5.38 | |